Mathematical model of a personalized neoantigen cancer vaccine and the human immune system.

Cancer vaccines are an important component of the cancer immunotherapy toolkit enhancing immune response to malignant cells by activating CD4+ and CD8+ T cells. Multiple successful clinical applications of cancer vaccines have shown good safety and efficacy. Despite the notable progress, significant...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marisabel Rodriguez Messan, Osman N Yogurtcu, Joseph R McGill, Ujwani Nukala, Zuben E Sauna, Hong Yang
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/34612679abed4dbf841986552536e7d1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:34612679abed4dbf841986552536e7d1
record_format	dspace
spelling	oai:doaj.org-article:34612679abed4dbf841986552536e7d12021-12-02T19:57:43ZMathematical model of a personalized neoantigen cancer vaccine and the human immune system.1553-734X1553-735810.1371/journal.pcbi.1009318https://doaj.org/article/34612679abed4dbf841986552536e7d12021-09-01T00:00:00Zhttps://doi.org/10.1371/journal.pcbi.1009318https://doaj.org/toc/1553-734Xhttps://doaj.org/toc/1553-7358Cancer vaccines are an important component of the cancer immunotherapy toolkit enhancing immune response to malignant cells by activating CD4+ and CD8+ T cells. Multiple successful clinical applications of cancer vaccines have shown good safety and efficacy. Despite the notable progress, significant challenges remain in obtaining consistent immune responses across heterogeneous patient populations, as well as various cancers. We present a mechanistic mathematical model describing key interactions of a personalized neoantigen cancer vaccine with an individual patient's immune system. Specifically, the model considers the vaccine concentration of tumor-specific antigen peptides and adjuvant, the patient's major histocompatibility complexes I and II copy numbers, tumor size, T cells, and antigen presenting cells. We parametrized the model using patient-specific data from a clinical study in which individualized cancer vaccines were used to treat six melanoma patients. Model simulations predicted both immune responses, represented by T cell counts, to the vaccine as well as clinical outcome (determined as change of tumor size). This model, although complex, can be used to describe, simulate, and predict the behavior of the human immune system to a personalized cancer vaccine.Marisabel Rodriguez MessanOsman N YogurtcuJoseph R McGillUjwani NukalaZuben E SaunaHong YangPublic Library of Science (PLoS)articleBiology (General)QH301-705.5ENPLoS Computational Biology, Vol 17, Iss 9, p e1009318 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Biology (General) QH301-705.5
spellingShingle	Biology (General) QH301-705.5 Marisabel Rodriguez Messan Osman N Yogurtcu Joseph R McGill Ujwani Nukala Zuben E Sauna Hong Yang Mathematical model of a personalized neoantigen cancer vaccine and the human immune system.
description	Cancer vaccines are an important component of the cancer immunotherapy toolkit enhancing immune response to malignant cells by activating CD4+ and CD8+ T cells. Multiple successful clinical applications of cancer vaccines have shown good safety and efficacy. Despite the notable progress, significant challenges remain in obtaining consistent immune responses across heterogeneous patient populations, as well as various cancers. We present a mechanistic mathematical model describing key interactions of a personalized neoantigen cancer vaccine with an individual patient's immune system. Specifically, the model considers the vaccine concentration of tumor-specific antigen peptides and adjuvant, the patient's major histocompatibility complexes I and II copy numbers, tumor size, T cells, and antigen presenting cells. We parametrized the model using patient-specific data from a clinical study in which individualized cancer vaccines were used to treat six melanoma patients. Model simulations predicted both immune responses, represented by T cell counts, to the vaccine as well as clinical outcome (determined as change of tumor size). This model, although complex, can be used to describe, simulate, and predict the behavior of the human immune system to a personalized cancer vaccine.
format	article
author	Marisabel Rodriguez Messan Osman N Yogurtcu Joseph R McGill Ujwani Nukala Zuben E Sauna Hong Yang
author_facet	Marisabel Rodriguez Messan Osman N Yogurtcu Joseph R McGill Ujwani Nukala Zuben E Sauna Hong Yang
author_sort	Marisabel Rodriguez Messan
title	Mathematical model of a personalized neoantigen cancer vaccine and the human immune system.
title_short	Mathematical model of a personalized neoantigen cancer vaccine and the human immune system.
title_full	Mathematical model of a personalized neoantigen cancer vaccine and the human immune system.
title_fullStr	Mathematical model of a personalized neoantigen cancer vaccine and the human immune system.
title_full_unstemmed	Mathematical model of a personalized neoantigen cancer vaccine and the human immune system.
title_sort	mathematical model of a personalized neoantigen cancer vaccine and the human immune system.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/34612679abed4dbf841986552536e7d1
work_keys_str_mv	AT marisabelrodriguezmessan mathematicalmodelofapersonalizedneoantigencancervaccineandthehumanimmunesystem AT osmannyogurtcu mathematicalmodelofapersonalizedneoantigencancervaccineandthehumanimmunesystem AT josephrmcgill mathematicalmodelofapersonalizedneoantigencancervaccineandthehumanimmunesystem AT ujwaninukala mathematicalmodelofapersonalizedneoantigencancervaccineandthehumanimmunesystem AT zubenesauna mathematicalmodelofapersonalizedneoantigencancervaccineandthehumanimmunesystem AT hongyang mathematicalmodelofapersonalizedneoantigencancervaccineandthehumanimmunesystem
_version_	1718375769243123712

Mathematical model of a personalized neoantigen cancer vaccine and the human immune system.

Ejemplares similares